Abu Dhabi’s state-run gas producer aims to increase exports of liquefied natural gas and other fuel cargoes further in the fourth quarter as more vessels transit the Strait of Hormuz, according to the company’s finance chief

Aber Kawas just made history as the first Palestinian American elected to the New York State Senate. AJ+ spoke with the democratic socialist about Americans’ disillusionment with the status quo and what led her to campaign.

AbCellera - FY2026 Q3 Earnings $ABCL $12.40 [-0.50% AH] ✅ Revenue: $10.6M (Est: $5.4M) [+19% YoY] ✅ EPS: -$0.13 (Est: -$0.18) [vs -$0.19 YoY] Segment Revenue: - Research fees: $10.5M [+20% YoY] - Licensing and royalty: $0.1M [-35% YoY] Additional Metrics: - Revenue up 163% QoQ from $4.1M - R&D expenses: $43.5M vs $55.0M YoY - SG&A expenses: $13.6M vs $25.0M YoY - Operating loss: $53.3M vs $76.3M YoY - Net loss: $40.8M vs $57.1M YoY - Cash and marketable securities: over $790M - Total available liquidity: over $890M, includes over $100M of non-dilutive government funding - Closed a $200M offering of common shares and pre-funded warrants in the quarter - Partner-led programs with an AbCellera downstream stake: 34 (down from 44 at Dec 31, 2025) Pipeline Update: - Positive top-line Phase 2 data for ABCL635 in hot flashes (moderate and severe VMS), late-stage development planned to start in 2027 - Phase 1 data for ABCL575 (OX40 ligand, atopic dermatitis) met all endpoints. No plan to develop it past Phase 1 - Three new programs advanced into IND-enabling work: ABCL992, ABCL385 and ABCL646